Radioligands in Oncology Program Growth and Trends

This technical report outlines the recent growth and diversification of radioligand therapy in oncology, emphasizing the historical context and current trends. It describes how radioligand therapy, while often perceived as a new modality, has roots in earlier treatments like Zevalin and Bexxar. The report details the acceleration in program initiation, driven by advancements in imaging, payload chemistry, and sponsor confidence. It highlights the dominance of prostate cancer and neuroendocrine tumors in radioligand development, while also noting emerging interests in breast cancer and glioblastoma. The report explains that while the targets remain stable, innovation is occurring in payload strategies, particularly with the exploration of alpha emitters. It discusses the factors contributing to the current growth, including improved manufacturing processes, clearer clinical workflows, and lessons learned from past failures. The report concludes by emphasizing the importance of execution discipline as the field expands beyond its traditional strongholds.